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Abstract
Background: Atrial fibrillation (AF) represents the most common sustained cardiac arrhythmia. A service evaluation
was carried out at an anticoagulation clinic in Newcastle upon-Tyne to explore the efficacy of introducing self-testing
of anticoagulation status for AF patients on warfarin. The analysis presented aims to assess the potential cost savings
and clinical outcomes associated with introducing self-testing at a clinic in the Northeast of England, and to determine
the cost-effectiveness of a redesigned treatment pathway including genetic testing and self-testing components.
Methods: Questionnaires were administered to individuals participating in the service evaluation to understand the
patient costs associated with clinical monitoring (139 patients), and quality-of-life before and after the introduction of
self-testing (varying numbers). Additionally, data on time in therapeutic range (TTR) were captured at multiple time
points to identify any change in outcome. Finally, an economic model was developed to assess the cost-effectiveness
of introducing a redesigned treatment pathway, including genetic testing and self-testing, for AF patients.
Results: The average cost per patient of attending the anticoagulation clinic was £16.24 per visit (including carer costs).
Costs were higher amongst patients tested at the hospital clinic than those tested at the community clinic.
Improvements in quality-of-life across all psychological topics, and improved TTR, were seen following the introduction
of self-testing. Results of the cost-effectiveness analysis showed that the redesigned treatment pathway was less costly
and more effective than current practice.
Conclusions: Allowing AF patients on warfarin to self-test, rather than attend clinic to have their anticoagulation status
assessed, has the potential to reduce patient costs. Additionally, self-testing may result in improved quality-of-life and
TTR. Introducing genetic testing to guide patient treatment based on sensitivity to warfarin, and applying this in
combination with self-testing, may also result in improved patient outcomes and reduced costs to the health service in
the long-term.
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Background
Atrial fibrillation (AF) represents the most common sus-
tained cardiac arrhythmia, affecting more than 6 million
people in Europe [1]. Vascular thrombosis and embolism
are major causes of morbidity and mortality. AF preva-
lence and its associated service pressures are increasing
in part due to a growing proportion of over 65 s in the
population, but also because actual AF prevalence is
likely to be much higher than predicted, as many pa-
tients with AF remain undiagnosed [2].
Two types of oral anticoagulants have been licensed for
use in the UK for the treatment of AF [3]: warfarin and
direct oral anticoagulants (DOACs). Warfarin has a nar-
row therapeutic window and its impact is vulnerable to
variable metabolism; a major reason for the wide variation
in optimal dose. For this reason, patients on warfarin need
to be routinely monitored to ensure that their inter-
national normalised ratio (INR) is within the desired
range. In contrast, DOACs have a wider therapeutic win-
dow than warfarin and are marketed with “no monitoring
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required” status [4]. However, they cost the UK National
Health Service (NHS) significantly more money than war-
farin, with expenditure on anticoagulants increasing by
approximately £400 million in the 2017–18 financial year
due to the increased use of DOACs [4].
Currently, AF patients attending their GP will typically
be prescribed either warfarin or a DOAC. However, it has
been known for two decades that around 3% of the popu-
lation with north European ancestry carry two CYP2C9
variants plus a variant in the vitamin K-related VKORC1,
which make them exquisitely sensitive to warfarin and
more liable to overdose [5–7]. Around a third of the
population have one or two of these variants, making the
choice of warfarin a more finely balanced decision. The
EU-PACT trial, where Newcastle was one of the recruit-
ment centres, tested the effect of pharmacogenetic-guided
warfarin dosing on anticoagulation outcomes with the aid
of point-of-care genetic testing, and demonstrated clinical
benefits, improved quality of patient care, increased time
in therapeutic range (TTR), and fewer incidents of over-
anticoagulation [8].
INR monitoring services, which are used to check the
impact of warfarin on the patient, have changed little in
recent years despite evidence that shows self-monitoring
of anticoagulation status is both clinically and cost-
effective compared with standard monitoring [9, 10]. Self-
monitoring has also been shown to increase TTR [11, 12].
This study aims to assess the economic impact of both
of these innovations (genetic testing and self-testing of
anticoagulation status for patients on warfarin), using
patient data from a service evaluation carried out at a
Newcastle-upon-Tyne anticoagulation clinic and an eco-
nomic model developed based on published literature.
Methods
The analysis is split into two sections:
(1) An evaluation of the patient cost savings and
consequences of implementing self-testing of antic-
oagulation status for individuals currently undergo-
ing warfarin treatment at a Newcastle-upon-Tyne
anticoagulation clinic (based on responses to
patient-completed cost and quality-of-life question-
naires and data on TTR pre- and post-
intervention).
(2) An evaluation of the cost-effectiveness of imple-
menting a redesigned treatment pathway (including
genetic testing of warfarin sensitivity, and self-
testing) compared to current practice, based on a
decision-analytic model.
Cost-consequence analysis
A cost-consequence analysis was conducted to estimate
the change in patient costs and outcomes (TTR and
quality-of-life) after undergoing self-testing. All patients
on warfarin receiving monitoring at the anticoagulation
clinic were asked if they would like to undertake self-
testing as part of the service evaluation. Where patients
agreed, they received initial training and a competency
check from a clinic nurse 1 week later to ensure that
they could be signed off as competent to self-test. Base-
line data on patient costs and quality-of-life were col-
lected at initial training, before the competency check
was carried out and prior to the patient beginning self-
testing.
Patient costs
A questionnaire to estimate patient costs of attending
the anticoagulation clinic (time and travel questionnaire)
was developed and administered to patients at the clinic
(Additional file 1). Responses to the questionnaire could
be used to estimate the average patient cost of attending
clinic and the cost savings that could be made by pa-
tients as a result of reducing their attendance at clinic.
For costs of patient (and carer) time, the time that they
have indicated that they spend travelling to and from the
anticoagulation clinic, as well as the time spent at the
clinic, was combined with information on the type of ac-
tivity, i.e. employment/leisure etc., that was displaced by
accessing care. Hourly costs for these activities were de-
rived from routine sources for working and non-working
time [13, 14]. The cost of time was valued at the national
median wage rate per hour if the patient (and/or carer)
missed paid work [13], while the cost of leisure time was
valued at the Department of Transport cost per hour of
leisure time [14]. Out-of-pocket monetary costs (if ap-
plicable) for accessing care were taken directly from re-
sponses to the questionnaire where the patient (and/or
carer) travelled by public transport and, where the pa-
tient (and/or carer) travelled by car, monetary costs were
estimated by combining information on the distance
travelled with the cost of travel per mile, derived from
routine sources [14]. Total cost of accessing care per pa-
tient could then be estimated. Costs were estimated for
a 2018 price year (£).
Quality-of-life
A quality-of-life questionnaire (Sawicki, 1999 [15]) was
administered to patients at baseline and 6months after
beginning self-testing to understand changes in patient
satisfaction pre- and post-intervention (Additional file 2).
The Anticoagulation Treatment (Warfarin) Question-
naire is a 32-item measure that has been used to meas-
ure differences in quality-of-life between patients who
receive warfarin and DOACs and between patients who
undergo clinical examination and self-management of
warfarin treatment [15]. Each of the 32 individual ques-
tions is scored from one (total disagreement) to six (total
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agreement) and groups of individual statements are
combined into five broad psychological topics: (1) Med-
ical treatment satisfaction, (2) Self-efficacy, (3) General
psychological distress, (4) Daily hassles, and (5) Strained
social network. A mean score of between one and six
can then be estimated for each of the individual topics.
Improvements in quality-of-life are indicated by higher
scores for the ‘Medical treatment satisfaction’ and ‘Self-
efficacy’ topics, and by lower scores for the ‘General psy-
chological distress’, ‘Daily hassles’ and ‘Strained social
network’ topics. Mean scores for each topic were esti-
mated at baseline and at 6 months. The mean difference
in score for each psychological topic was then estimated,
and a paired samples t-test was carried out to look at
the statistical significance of any differences in scores.
TTR
Finally, data on TTR (percentage of time in past 6
months in which INR was in target range) were col-
lected from the DAWN AC System on all patients
undergoing self-testing. TTR was calculated using the
Rosendaal method, which looks at two INRs at a time
and calculates the proportion of the line that is cur-
rently in range (each individual has their own personal
target INR range) [16]. These data were collected three,
and six, months pre-intervention and 6 months post-
intervention, and were analysed to understand the
changes in TTR outcomes (percentage of TTR) for pa-
tients undergoing self-testing.
Cost and clinical data were analysed and presented at
an average level. Analyses were carried out using Stata
15 statistical software. Data from as many patients as
possible were collected on the different outcomes at
relevant time points. This led to some variability in the
number of patients included in each outcome analysis.
Cost-effectiveness analysis
This section describes the long-term economic model
developed to estimate the costs and effects of introdu-
cing a redesigned treatment pathway (including genetic
testing and self-testing) for AF patients, compared with
current clinical practice. The model was designed and
populated based on information from published litera-
ture. A description of the included model parameters
can be seen in Additional file 3. The CHEERS reporting
guidelines were followed in presenting details of the eco-
nomic model [17].
Model description
An economic model, developed as a Markov cohort
model, was built in TreeAge Pro® (TreeAge Software,
Inc., Williamstown, MA, USA) [18] to estimate the cost-
effectiveness of introducing the full redesigned pathway
for management of AF patients, compared with current
clinical practice. The population considered was patients
with atrial fibrillation aged 65 and over. The model
structure is shown in Additional file 4: Figure S1.
Patients begin the model at a point where they can re-
ceive either current patient management or redesigned
management. Where patients receive current practice,
they are initially prescribed either warfarin or a DOAC
(DOAC assumed to be dabigatran based on clinical evi-
dence available for this medication, although prescribing
practices vary across localities). The clinical pathways
following each choice of treatment are identical. All pa-
tients are initially assumed to be well on treatment, and
from this health state patients can go on to experience
an ischaemic stroke, myocardial infarction (MI), major
bleeding event, systemic embolism, or they may die. Al-
ternatively, patients may not experience any adverse
event and therefore, remain in the same health state. De-
pending on the events experienced during this clinical
pathway, patients move on to subsequent health states
‘post stroke with no deficit’, ‘post stroke with mild def-
icit’, ‘post stroke with major deficit’, depending on the
severity of the original non-fatal ischaemic stroke, ‘post
MI’ following a non-fatal MI, ‘post major bleed/intracra-
nial haemorrhage (ICH)’ following a non-fatal ICH, or
‘Dead’ following a fatal clinical event or from general
background mortality. Where patients do not experience
any adverse clinical event, or experience a systemic em-
bolism or extracranial haemorrhage and survive, they re-
turn to the ‘Well’ health state. In all post event health
states patients can either survive or die, with the mortal-
ity risk increased following a stroke or major bleed.
Where patients follow the redesigned pathway, they
begin by receiving a genetic test and are grouped as hav-
ing major sensitivity, moderate sensitivity or normal sen-
sitivity (to warfarin) based on the results of this test.
Patients then follow the same care pathways as described
previously, i.e. are prescribed either warfarin or a DOAC
and can go on to experience various adverse clinical
events, die or remain well.
Model assumptions
(1) Patients on warfarin undergoing clinical monitoring
with current practice are assumed to attend 11
clinic visits over the first 3 months (dose initiation
stage), and subsequently attend the clinic once per
month for monitoring.
(2) In the redesigned pathway, it is assumed that the
percentage of patients receiving warfarin varies
depending on genetic test results. Therefore,
patients with normal sensitivity have a higher
probability of receiving warfarin than those with
moderate and major sensitivity.
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(3) It is assumed that all warfarin patients in the
redesigned pathway are self-testing, regardless of
sensitivity status. It is assumed that these patients
are clinically monitored in the first 3 months fol-
lowing a genetic test and that from this point on-
wards they self-test only. This clinical monitoring in
the first 3 months following a genetic test is as-
sumed to be 75% the cost of clinical monitoring
with current practice, as genetic testing would re-
sult in the dose being stabilised quicker, as per
Janzic et al. [19]. However, in order to account for
the fact that patients with genotypes of high or low
warfarin sensitivity would be managed by intensified
anticoagulation care (monitoring at least twice per
month, rather than the monthly monitoring as-
sumed with current practice), in the model it is as-
sumed that in the first 3 months patients with
moderate or major sensitivity receive bi-monthly
monitoring for the first 3 months, before beginning
self-testing.
(4) It is assumed that the risk reduction for the
different clinical complications associated with self-
testing is the same, regardless of sensitivity status of
the patient.
(5) It is assumed that in the redesigned pathway,
warfarin patients continue to self-test even after ex-
periencing an adverse event, other than following a
major bleed or intracranial haemorrhage, in which
case patients switch to taking aspirin (current prac-
tice and redesigned pathway).
(6) Relative risks of experiencing a bleed or
thromboembolic event have been applied to the
clinical probabilities for patients on warfarin in the
redesigned pathway to account for the fact that
patients are self-testing. These relative risks are ap-
plied to the stroke, MI and systemic embolism
probabilities.
(7) In the redesigned pathway, probabilities of
experiencing a stroke and major bleed are based on
time in range and out of range and these values
vary at the three levels of sensitivity to warfarin
(normal/moderate/major). However, in the
redesigned pathway, the probabilities of
experiencing an MI or systemic embolism have not
been estimated in the same way, as these
probabilities are set in the usual care arm, i.e. not
based on time in range and out of range.
(8) In the redesigned pathway, patients on DOACs
follow the same pathway and have the same
likelihood of clinical events as patients on DOACs
in the current practice pathway. The only difference
between these patients is that in the redesigned
pathway, all patients initially receive a genetic test.
As with current practice, patients in the redesigned
pathway on a DOAC who survive stroke when on
dabigatran 110 mg switch to dabigatran 150 mg
twice daily. Patients who experience a major bleed
or intracranial haemorrhage on DOACs switch to
aspirin (as is also the case when on warfarin).
Assessment of costs and consequences
The model was run to obtain the expected values for
each strategy over the patient lifetime. The analysis was
designed to generate the incremental cost per quality-
adjusted life-year (QALY) gained. All costs were for a
2018 price year (£), and were inflated to this price year
where appropriate. Where available, and where appro-
priate, data were entered into the model as distributions
in order to fully incorporate the uncertainty around par-
ameter values so that a probabilistic sensitivity analysis
(PSA) could be undertaken. The PSA was run with 10,
000 simulations and probabilistic output was produced.
Deterministic sensitivity analyses were also conducted to
explore individual, and multiple, parameter variation and
the impact that this would have on the results. All costs
and health effects were considered from a UK NHS and
personal social services (PSS) perspective and were dis-
counted at an annual rate of 3.5% [20].
Results
Cost-consequence analysis
Patient costs
The average cost of attending the warfarin clinic was es-
timated based on patient responses to the ‘Cost of at-
tending anticoagulation clinic’ questionnaire (Additional
file 1). Patient data for 139 patients were included in the
analysis. Costs of attending the anticoagulation clinic are
shown in Table 1. Based on all responses received, the
average cost per patient of attending the anticoagulation
clinic was £13.86 per visit, with this cost increasing to
£16.24 per patient when the cost of the carer’s time was
also included. Only 22 patients in total reported that
they required help in travelling to the clinic. Respon-
dents were also asked to indicate how often they have
their blood tested, and using this information along with
the average cost per visit, the average monthly cost per
patient of attending clinic could be estimated. These
costs were £16.43 per month excluding carer costs, and
£18.75 including carer costs. Over 1 year, this would
Table 1 Patient costs of attending anticoagulation clinic
Variable Mean (£) (Standard
deviation (£))
Cost per patient per visit 13.86 (11.47)
Cost per patient per visit (including carer costs) 16.24 (14.29)
Monthly cost per patient 16.43 (29.21)
Monthly cost per patient (including carer costs) 18.75 (29.75)
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translate to savings of £197.16 per patient excluding
carer costs, and £225.00 including carer costs, were self-
testing to be introduced for AF patients on warfarin.
A subgroup analysis was also conducted to compare
costs incurred by patients undergoing testing at the hos-
pital clinic with patients undergoing testing at the com-
munity clinic. Individual visit, and monthly, costs were
higher amongst patients who underwent testing at the
hospital clinic (£15.11 and £20.20, respectively (without
carer costs)) compared to those who attended the com-
munity clinic (£12.21 and £11.14, respectively).
Quality-of-life
The quality-of-life of all patients was estimated at base-
line and at 6 months following the introduction of the
self-testing intervention. Average quality-of-life scores
for the five individual psychological topics, at baseline
and 6months, as well as the minimum and maximum
average scores identified, are presented in Table 2 below.
A varying number of patients completed all questions
for each of the psychological topics, and this variation is
also shown. The number of patients who completed the
questionnaire at baseline was greater than the number
who completed the questionnaire at 6 months, primarily
because many patients had not yet reached 6months
self-testing upon completion of the evaluation. Add-
itional numbers may then have been missing at each
time point for each of the psychological topics due to
failure to complete specific questions on each of the
topics. The statistical significance of any differences in
mean scores was tested using the paired samples t-test,
with the null hypothesis being that the difference be-
tween mean scores is zero. The null hypothesis could be
rejected where the associated p-value was less than 0.05,
indicating a statistically significant difference in scores.
Results of the t-test were based on the total number of
patients who answered all questions related to each psy-
chological topic at the two time points.
Results indicate that at 6 months, following the intro-
duction of self-testing, the mean scores for medical
treatment satisfaction and self-efficacy are higher than at
baseline (+ 0.63 and + 0.21, respectively) while the mean
scores for general psychological distress, daily hassles
and strained social network are all lower than at baseline
(− 0.23, − 0.11 and – 0.20, respectively). For the medical
treatment satisfaction, general psychological distress,
and strained social network psychological topics, we can
reject the null hypothesis that the difference between
mean scores is zero, i.e. p-value < 0.05. Therefore, there
is a statistically significant difference between the scores.
In a separate analysis, differences in quality-of-life be-
tween patients monitored at the hospital clinic and pa-
tients monitored at the community clinic were also
assessed at baseline. Improved quality-of-life scores for
the medical treatment satisfaction, strained social net-
work, self-efficacy and daily hassles topics were seen for
patients monitored at the community clinic, while for
the general psychological distress topic, quality-of-life
was higher for patients monitored at the hospital clinic.
TTR
TTR percentage prior to, and following, the introduction
of self-testing for warfarin patients, and change in TTR
percentage, are presented in Tables 3 and 4 below. Data
on TTR were collected 3 and 6months before the imple-
mentation of self-testing, and 6months following its
introduction. Data for 135 patients were collected 6
months prior to the introduction of self-testing and the
average TTR score was 71%. Data for 137 patients were
collected 3 months prior and the average TTR score was
73%. For 109 of these patients, data 6 months following
the introduction of self-testing were collected and the
average TTR score was 75%. For 105 patients, data were
collected both 6 months prior to and 6months following
the introduction of self-testing (32 of the patients in-
cluded in the dataset had not yet reached the point at
which they would require the 6 month test). The average
Table 2 Quality-of-life scores
Psychological
Topics
Number of
patients
Baseline
mean (SD)
Min Max Number of
patients
6-month
mean (SD)
Min Max Difference
compared to
baseline
Paired samples t-test p-
value (n patients)
Medical treatment
satisfaction
119 4.97 (1.08) 1 6 88 5.60 (0.55) 3.6 6 + 0.63 0.00 (72)
Self-efficacy 125 4.40 (1.40) 1.25 6 88 4.61 (1.32) 2.25 6 + 0.21 0.11 (76)
General
psychological
distress
124 2.32 (1.07) 1 5.43 87 2.09 (0.91) 1 4.71 - 0.23 0.03 (74)
Daily hassles 117 2.34 (0.83) 1 5 85 2.23 (0.78) 1 4.13 - 0.11 0.15 (70)
Strained social
network
126 1.72 (0.88) 1 4.75 88 1.52 (0.63) 1 3.75 - 0.2 0.01 (77)
Minimum score = one, maximum score = six. Mean, min and max scores are calculated based on responses from patients who completed all relevant questions for
a given psychological topic
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increase in percentage of TTR for those patients for
whom data were collected 6 months before and after the
introduction of self-testing was 3%. For 108 patients,
data were collected 3 months prior to and 6months fol-
lowing the introduction of self-testing. The average in-
crease in percentage of TTR for those patients for whom
data were collected 3 months before and 6months after
the introduction of self-testing was 0.5%.
Cost-effectiveness analysis
This section presents the results of the cost-effectiveness
analysis. Results of the base-case analysis are presented
first, followed by results of the sensitivity analyses.
Base-case analysis
The base-case results indicate that the redesigned treat-
ment pathway is cost-effective, and that current practice
is absolutely dominated, i.e. less effective (−0.01) and
more costly (+£1397). Results from the PSA show that
the redesigned treatment pathway has a higher probabil-
ity of being cost-effective across a range of willingness-
to-pay (WTP) thresholds (Additional file 5: Figure S2).
The cost-effectiveness plane (Additional file 6: Figure
S3) also shows that although the majority of points are
clustered around zero cost and zero effect, there is a
marginally higher number of points in the south-east
quadrant (indicating that the intervention is more effect-
ive and less costly).
Sensitivity analysis
A number of sensitivity analyses were also carried out to
explore the impact that key parameter variation (with all
other parameters fixed at base-case values) had on the
model results (Table 5). Firstly, the impact of varying the
percentage of patients who are prescribed warfarin in
current practice was explored. When this probability
was decreased to 0.1 (i.e. 90% of patients prescribed
DOAC), current practice was found to be even more ex-
pensive relative to the redesigned pathway. However, in
this scenario current practice was now more effective (+
0.08) than the new treatment pathway (although not
cost-effective based on a maximum WTP threshold of
£40,000). When this probability was increased to 0.9, the
redesigned pathway was now more expensive than
current practice but even more effective (+ 0.19) than in
the base-case analysis. The resulting incremental cost-
effectiveness ratio (ICER) in this scenario analysis was
£8195, meaning that the redesigned treatment pathway
would be considered cost-effective.
Separate exploratory analyses were conducted to ex-
plore the impact of increasing the percentage of patients
with normal sensitivity, and major sensitivity, to warfarin
following genetic testing in the redesigned treatment
pathway. None of these variations changed the base-case
decision. Finally, on the basis of clinical advice (clinical
experts involved in the study), the percentage of patients
with normal sensitivity to warfarin who are prescribed
warfarin following a genetic test may not be as high as
90%, as assumed in the base-case analysis. Therefore,
this probability was decreased to 0.5 and 0.1 in two sep-
arate sensitivity analyses. Following these variations, the
redesigned pathway was more expensive than current
practice (with cost of the new pathway increasing as this
probability is lowered), while effectiveness also increased.
In both scenarios, the redesigned treatment pathway
remained cost-effective.
Discussion
An economic analysis was carried out to explore the
costs and health outcomes associated with the introduc-
tion of two innovations (genetic testing of warfarin sen-
sitivity and self-testing of anticoagulation status) for the
management of patients with atrial fibrillation. Two sep-
arate analyses were conducted; a cost-consequence ana-
lysis focussing on self-testing, using patient data
collected at Newcastle-upon-Tyne anticoagulation clinic,
and a cost-effectiveness analysis of a redesigned treat-
ment pathway, informed by the literature.
Results from the cost-consequence analysis highlight
the cost savings that could be made by patients on war-
farin by introducing self-testing as a replacement for
clinical monitoring of anticoagulation status. An average
saving of £18.75 per patient per month (including carer
costs) could be made by patients by eliminating the re-
quirement for patients to travel to the anticoagulation
clinic to be monitored. Costs are incurred through pa-
tients having to take time off work and other activities,
travel to clinic and pay out of pocket for parking and
public transport (if applicable), and the introduction of
self-testing can remove these costs. The results also
highlight the fact that costs incurred are higher for
Table 3 TTR % prior to, and following, the introduction of self-
testing
Variable Mean (%) (SD (%))
TTR 6 months prior 71 (23)
TTR 3 months prior 73 (22)
TTR 6 months following 75 (17)
Table 4 Difference in TTR % prior to, and following, the
introduction of self-testing
Variable Mean change (%)
(SD (%))
Difference between TTR 6 months prior and 6
months following introduction of self-testing
+ 3 (23)
Difference between TTR 3 months prior and 6
months following introduction of self-testing
+ 0.5 (23)
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patients who attend the hospital clinic compared to
those who attend the community clinic due to the fact
that patients attending the hospital clinic will typically
have to travel longer distances, will often find it more
difficult to find parking and will regularly have to wait
longer than patients who attend the community clinic
(many of whom will be seen at a specific appointment
time). In our sample, 58% of patients underwent moni-
toring at the hospital clinic. Although in practice, data
indicate that most patients are in fact monitored at the
community clinic, these results highlight the cost savings
that could be made by reducing the percentage of pa-
tients monitored at the hospital clinic even further. Clin-
ical results from the cost-consequence analysis also
show an average improvement in quality-of-life scores
(across all psychological topics), and an average increase
in time in therapeutic range for patients following the
introduction of self-testing.
A cost-effectiveness analysis, informed by the litera-
ture, was also conducted to explore the long-term
costs and outcomes associated with the introduction
of a full redesigned pathway for patients receiving
treatment for atrial fibrillation. Base-case probabilistic
results show the high likelihood of the new pathway
being cost-effective across all willingness-to-pay
thresholds. Additionally, multiple sensitivity analyses
were carried out, none of which had an impact on
the base-case decision, with the intervention strategy
remaining dominant (less costly and more effective)
in most. However, sensitivity analyses conducted do
indicate that the percentage of patients who are cate-
gorised as having normal/moderate/major sensitivity
following the genetic test, and the percentage of pa-
tients prescribed warfarin/DOAC at each level of sen-
sitivity, are strong drivers of costs and effects.
The analysis presented here is unique in that it is the
first time that real-world data from patients undergoing
self-testing who were previously clinically monitored at
an anticoagulation clinic in the Northeast of England,
have been used in an economic analysis. Results of our
cost-effectiveness analysis are in line with previous eco-
nomic evaluations which have shown the potential cost-
effectiveness of point-of-care tests for the self-
monitoring of anticoagulation status [10]. However, our
analysis is novel in that it combines both genetic testing
and self-testing components in one model, which is a
first for the UK setting.
There are limitations to this analysis, primarily
around the uncertainty surrounding many of the par-
ameter estimates included in the cost-effectiveness ana-
lysis. Consequently, a number of assumptions were
made in developing and populating the economic
model. Most notably, there was a lack of information
available on how the genetic test results would impact
the percentage of patients receiving warfarin as op-
posed to a DOAC. Additionally, in the model it was as-
sumed that self-testing would have the impact of
reducing the probability of experiencing a complication
but it was unknown how the sensitivity status of the pa-
tient would impact this probability. Therefore, it was
assumed that the risk reduction associated with self-
testing was the same regardless of genetic test results.
Where possible, these assumptions were explored in
sensitivity analysis. Variation of the probability of re-
ceiving warfarin when identified as having normal sen-
sitivity was conducted, but this variation did not result
in a change in the cost-effectiveness decision. Future
economic analyses in this area should attempt to use
data which may remove some of the uncertainty
present in the existing model. Finally, results from the
cost-consequence analysis highlight the economic and
clinical benefits that could result from a switch to self-
testing and a cost-effectiveness model now exist for re-
analysis once additional data become available.
Conclusions
The introduction of self-testing for atrial fibrillation pa-
tients on warfarin has the potential to reduce costs for
patients and improve patient outcomes, based on data
Table 5 Sensitivity analyses
Analysis Cost difference
vs. current
practice (£)
QALY
difference vs.
current
practice
ICER for ‘redesigned
treatment pathway’ (cost
per QALY gained) (£)
Base-
case
result
−1397 0.01 Dominant
Sensitivity analysis
Probability of taking warfarin with current practice (base-case 0.4)
0.1 − 3285 −0.08 42,040a
0.9 1522 0.19 8195
Reduction in probability of having moderate sensitivity in redesigned
pathway (base-case 0.27) (increasing probability of having normal
sensitivity)
0.20
− 1693 0.03 Dominant
0 − 2322 0.06 Dominant
Increase in probability of having major sensitivity in redesigned
pathway (base-case 0.07)
0.15
− 1081 0.02 Dominant
0.6 1087 0.04 30,139
Decrease in probability of taking warfarin if normal sensitivity in
redesigned pathway (base-case 0.9)
0.5 50 0.05 1089
0.1 1585 0.07 23,012
aICER for current practice
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collected from a service evaluation at an anticoagulation
clinic in the Northeast of England. Additionally, a rede-
signed treatment pathway including genetic testing and
self-testing components could potentially reduce costs to
the health care service and improve long-term clinical
outcomes for patients with atrial fibrillation.
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